IRD Opus Genetics, Inc.

QT51

Latest market price

3.70

+0.03+0.82%

Overview Short InterestFilings

IRDQT51Opus Genetics, Inc.·NASDAQ

Overview Short InterestFilings

3.70+0.82%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

QURE-7.49%$22.97 RARE+1.24%$16.30 NUVB-3.57%$4.59 TRAX-0.07%$45.05 NTLA-6.50%$11.66 ABSI-12.94%$9.69 URGN+5.01%$34.36 MAZE-3.53%$30.37

Snapshot

Index	—	P/E	—	EPS (ttm)	-1.27	Insider Own	22.59%	Shs Outstand	83.20M	Perf Week	11.45%

Market Cap	307.82M	Forward P/E	—	EPS next Y	-0.70	Insider Trans	-12.63%	Shs Float	35.25M	Perf Month	-19.21%

Enterprise Value	253.82M	PEG	—	EPS next Q	-0.14			Short Float	37.84%	Perf Quarter	-0.27%

Income	-108.00M	P/S	30.78	EPS this Y	—			Short Ratio	5.40	Perf Half Y	-29.12%

Sales	10.00M	P/B	—	EPS next Y	—	ROA	-115.75%	Short Interest	13.34M	Perf YTD	84.08%

Book/sh	-0.16	P/C	3.46	EPS next 5Y	—	ROE	—	52W High	7.07 -47.67%	Perf Year	87.82%

Cash/sh	1.07	P/FCF	—	EPS past 3/5Y	—	ROIC	-59.29%	52W Low	1.70 117.65%	Perf 3Y	—

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	-29.53% —	Gross Margin	99.87%	Volatility	6.78% 7.46%	Perf 5Y	—

Dividend TTM	—	EV/Sales	25.38	EPS Y/Y TTM	—	Oper. Margin	-513.47%	ATR (14)	0.32	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	12.19	Sales Y/Y TTM	-33.33%	Profit Margin	-1091.82%	RSI (14)	40.60	Recom	2.00

Dividend Gr. 3/5Y	—	Current Ratio	12.19	EPS Q/Q	-16.67%	SMA20	-6.91%	Beta	1.15	Target Price	12.60

Payout	0.00%	Debt/Eq	—	Sales Q/Q	-66.67%	SMA50	-17.09%	Rel Volume	0.35	Prev Close	3.67

Employees	28	LT Debt/Eq	—	Earnings	Nov 11	SMA200	-11.71%	Avg Volume	2.53M	Price	3.70

IPO Date	Jan 19, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	10.64% -71.27%	Net Debt/EBITDA	—	Volume	877,657	Change	0.82%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Sep-09-26	Reiterated	Oppenheimer	Outperform
Sep-09-26	Reiterated	Chardan Capital	Buy
Aug-07-26	Reiterated	RBC Capital	Outperform	$10 → $9.00
Jun-23-26	Initiated	RBC Capital	Outperform	$10
Jun-17-26	Reiterated	HC Wainwright & Co.	Buy	$8.00
May-21-26	Initiated	Leerink	Outperform	$10
Mar-11-26	Reiterated	Craig-Hallum		$9.00
Jan-20-26	Initiated	BTIG	Buy	$7.00
Nov-25-25	Initiated	Piper Sandler	Overweight	$7.00

Latest News· Times ET

Nov-02-26

Nov-02-2604:39PM

Opus Genetics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)globenewswire.com

Oct-29-26

Oct-29-2607:00AM

Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operationsglobenewswire.com

Oct-25-26

Oct-25-2608:02AM

Opus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA Approvalmarketbeat.com

Oct-21-26

Oct-21-2601:48PM

Sector Update: Healthcare Stocks Decline Wednesday AfternoonYahoo

07:00AM

Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindnessglobenewswire.com

Oct-16-26

Oct-16-2601:58PM

Opus Genetics Secures FDA Approval For Eye Drops – Set To Receive Milestone PaymentYahoo

12:00PM

Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopiaglobenewswire.com

Oct-15-26

Oct-15-2604:00PM

Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026globenewswire.com

Oct-13-26

Oct-13-2605:00PM

Wondering what's happening in today's after-hours session?ChartMill

07:00AM

Opus Genetics to Present at the Chardan Annual Healthcare Conferenceglobenewswire.com

Oct-08-26

Oct-08-2606:55PM

Could an FDA Nod for MR-141 Give Viatris (VTRS) and Opus Genetics (IRD) a Presbyopia Payoff?Yahoo

Oct-04-26

Oct-04-2607:30PM

Opus Genetics, Inc. (IRD) Presents at Euretina 2026 - SlideshowSeekingAlpha

Oct-01-26

Oct-01-2604:15AM

Opus Genetics, Inc. (NASDAQ:IRD) Receives Consensus Recommendation of “Moderate Buy” from Brokeragesdefenseworld.net

Sep-17-26

Sep-17-2604:39AM

Squarepoint Ops LLC Takes $1.36 Million Position in Opus Genetics, Inc. $IRDdefenseworld.net

Sep-16-26

Sep-16-2606:17PM

Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified?Yahoo

Company

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019
Total Revenue	10	14	11	19	—	—	—	—
Cost of Goods Sold Incl. D&A	0	0	0	0	—	—	—	—
Gross Profit	10	14	11	19	—	—	—	—
Selling, General and Administrative Excl. Other	22	22	18	12	—	—	—	—
Research and Development	38	31	27	18	—	—	—	—
Other Operating Expense	0	0	28	0	—	—	—	—
Operating Income	-49	-39	-62	-11	—	—	—	—
Interest Expense	3	1	0	1	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-55	-10	5	2	—	—	—	—
Net Income Before Taxes	-108	-50	-58	-10	—	—	—	—
Income Taxes	0	0	0	0	—	—	—	—
Consolidated Net Income	-108	-50	-58	-10	—	—	—	—
Net Income From Continuing Operations	-108	-50	-58	-10	—	—	—	—
Net Income	-108	-50	-58	-10	—	—	—	—
EPS (Recurring)	-1.27	-0.80	-2.15	-0.46	—	—	—	—
EPS (Basic, Before Extraordinaries)	-1.27	-0.80	-2.15	-0.46	—	—	—	—
EPS (Diluted)	-1.27	-0.80	-2.15	-0.46	—	—	—	—
EBITDA	-105	-48	-58	-10	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—
Price To Sales Ratio	35.15	89.30	2.92	—	—	—	—	—
Gross Margin	100.00	100.00	100.00	100.00	—	—	—	—
Operating Margin	-490.00	-278.57	-563.64	-57.89	—	—	—	—
Net Margin	-1,080.00	-357.14	-527.27	-52.63	—	—	—	—
Shares Outstanding	95	622	27	22	—	—	—	—
Market Capitalization	352	1,250	32	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
YERXA BENJAMIN R	President	Oct 23 '26	Sale	3.54	33,189	117,365	670,917	Oct 27
Gagnon Robert E.	Chief Financial Officer	Oct 23 '26	Sale	3.55	14,000	49,650	542,375	Oct 27
Magrath George	Chief Executive Officer	Oct 23 '26	Sale	3.58	9,591	34,384	2,038,894	Oct 27
SCHACHLE JOSEPH K	Chief Operating Officer	Oct 23 '26	Sale	3.56	4,767	16,994	286,673	Oct 27
Foundation Fighting Blindness Retinal Degeneration Fund	Director	Sep 30 '26	Sale	4.96	556,000	2,755,981	3,236,171	Oct 02
Magrath George	Chief Executive Officer	Sep 09 '26	Option Exercise	1.15	392,157	450,981	2,124,026	Sep 11
Gallagher Cam	Director	Sep 08 '26	Option Exercise	1.15	784,314	901,961	2,800,111	Sep 08
Gagnon Robert E.	Chief Financial Officer	Sep 03 '26	Sale	4.54	28,000	127,212	556,375	Sep 08
YERXA BENJAMIN R	President	Jul 23 '26	Sale	2.97	7,429	22,064	704,106	Jul 27
SCHACHLE JOSEPH K	Chief Operating Officer	Jul 23 '26	Sale	2.94	4,644	13,653	291,440	Jul 27
Magrath George	Chief Executive Officer	Jul 23 '26	Sale	2.95	9,475	27,926	1,731,869	Jul 27
Gagnon Robert E.	Chief Financial Officer	Jul 23 '26	Sale	2.95	7,783	22,942	584,375	Jul 27
Foundation Fighting Blindness Retinal Degeneration Fund	Director	May 18 '26	Sale	4.35	1,700,000	7,395,000	3,792,171	May 20
YERXA BENJAMIN R	President	Apr 23 '26	Sale	5.24	7,470	39,121	711,535	Apr 27
SCHACHLE JOSEPH K	Chief Operating Officer	Apr 23 '26	Sale	5.22	4,697	24,519	296,084	Apr 27

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.